Advertisement

Topics

Latest "ProEthic Pharmaceuticals" News Stories

03:17 EST 25th February 2018 | BioPortfolio

Here are the most relevant search results for "ProEthic Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about ProEthic Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ProEthic Pharmaceuticals for you to read. Along with our medical data and news we also list ProEthic Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProEthic Pharmaceuticals Companies for you to search.

Showing "ProEthic Pharmaceuticals" News Articles 1–25 of 7,700+

Relevant

Vitruvias Therapeutics Inc. Completes Series A Preferred Financing Led by JW Asset Management and Perceptive Advisors

Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led by JW Asset Management LLC, and Perceptive Advisors. The Company is also pleased to announce that Jason Wild of JW Asset Management, Mich...


Salix Pharmaceuticals (SLXP) vs. Its Rivals Head to Head Survey

Salix Pharmaceuticals is one of 19 public companies in the "Specialty & Advanced Pharmaceuticals" industry, but how does it contrast to its rivals? We will compare Salix Pharmaceuticals to related companies based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, risk, valuation and earnings. Salix Pharmaceuticals' rivals have higher revenue ...

Financial Contrast: Arena Pharmaceuticals

Arena Pharmaceuticals and Sunesis Pharmaceuticals are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership. Arena Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the ...


GW Pharmaceuticals plc: GW Pharmaceuticals Announces Proposed Public Offering of ADSs

LONDON, 2017-12-05 22:17 CET (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing nov...

Critical Analysis: Sagent Pharmaceuticals

Sagent Pharmaceuticals and Lannett are both pharmaceuticals - nec companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Sagent Pharmaceuticals has higher earnings, but lower revenue than Lannett.

Acura Pharmaceuticals (ACUR) vs. Avadel Pharmaceuticals plc a "...

Complete the form below to receive the latest headlines and analysts' recommendationsfor Acura Pharmaceuticals with our free daily email newsletter: Acura Pharmaceuticals vs. Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Head to Head Review Acura Pharmaceuticals and Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordi...

Contrasting Pacira Pharmaceuticals

Pacira Pharmaceuticals and Lannett Co are both small-cap pharmaceuticals - nec companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership. This is a summary of current ratings and target prices for Pacira Pharmaceuticals and Lannett Co, as r...

GW Pharmaceuticals ADR: Kommt es jetzt zum Ausbruch? Trading-Chance!

Es gibt ein weiteres Unternehmen GW Pharmaceuticals, das vorwiegend Cannabis herstellt und somit als "Pflanzenzüchter" zu werten ist. GW Pharmaceuticals ADR ist ein Biotech-Unternehmen, das sich zw...

GW Pharmaceuticals plc: GW Pharmaceuticals kündigt geplantes öffentliches Angebot von American Depositary Shares an

LONDON, 7. Dez. 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" oder das "Unternehmen"), ein biopharmazeutisches Unternehmen, das auf die Entdeckung, Entwicklung und Vermarktun...

Cerecor to acquire TRx Pharmaceuticals

Cerecor has entered into an agreement to TRx Pharmaceuticals and its subsidiary Zylera Pharmaceuticals.

Imprimis launches Surface Pharmaceuticals subsidiary

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharmaceuticals. Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases by seeking FDA approval for three drug candidates for up to five indications. Surface’s drug candid...

FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) for Travelers' Diarrhea

Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the U.S. Food and Drug Administration (FDA) has granted b...

Deals this week: Valeant Pharmaceuticals International, Novan, Recursion Pharmaceuticals

Valeant Pharmaceuticals International plans to raise C$1bn ($801.37m) through the private placement of senior secured notes.

Contrasting Acura Pharmaceuticals (ACUR) & Avadel...

Acura Pharmaceuticals and Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations. 9.4% of Acura Pharmaceuticals shar...

Probably Relevant

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals Appoints John Zhang, MD, Ph.D. as Vice President, Research and Development

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / December 11, 2017 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment...

Pivot Pharmaceuticals Inc.: Pivot Pharmaceuticals Obtains Receipt from BCSC for Final Non-Offering Prospectus

VANCOUVER, BC / ACCESSWIRE / December 1, 2017 / Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) ("Pivot" or the "Company"), an emerging biopharmaceutical company engaged in the development and commercial...

Valeant Pharmaceuticals signs deal to sell Sprout Pharmaceuticals subsidiary

Valeant Pharmaceuticals International Inc. has signed a deal to sell its Sprout Pharmaceuticals subsidiary and its female sexual dysfunction drug to the company's former owners. Under the deal, Valeant will receive a six per cent royalty on sales of Addyi starting 18 months from the signing of the sale agreement.

Nasdaq Stockholm AB: Resumed trading in Immune Pharmaceuticals Inc. (329/17)

With reference to a press release published by Immune Pharmaceuticals Inc. today on November 13, 2017, at 16:45 CET, the trading in the shares of Immune Pharmaceuticals Inc. (IMNP, ISIN code US4525...

Pre-Market Technical Scan on Biotech Equities -- Portola Pharmaceuticals, Sarepta Therapeutics, ...

Portola Pharmaceuticals On Monday, shares in Californiaheadquartered Portola Pharmaceuticals Inc. recorded a trading volume of 714,344 shares. The stock ended the session 1.23% higher Read more...

Deals this week: Revance Therapeutics, GW Pharmaceuticals, Valeant Pharmaceuticals International

Revance Therapeutics intends to raise $175m through an underwritten public offering of the shares of its common stock. Underwriters will...Read More... The post Deals this week: Revance Therapeutics, GW Pharmaceuticals, Valeant Pharmaceuticals International appeared first on Pharmaceutical Technology.

Regeneron and ISA Pharmaceuticals form immuno-oncology collaboration

Regeneron Pharmaceuticals and ISA Pharmaceuticals have formed a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody.

Valeant to divest Sprout Pharmaceuticals to former owners

Valeant Pharmaceuticals International's affiliate has agreed to divest its female libido-pill business Sprout Pharmaceuticals to a buyer associated with the latter’s former shareholders.

Opiant Pharmaceuticals & Titan Pharmaceuticals to Explore New Approach to Opioid Use Disorder Treatment

NewsRelapse and fatal overdose among those with opioid use disorder is significantly higher than any other type of drug addiction.

Cantex Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia

WESTON, Fla., January 3, 2018 -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancers and other life-threatening disorders, today announced that the...

Veloxis Pharmaceuticals A/S: Veloxis Pharmaceuticals Announces Financial Calendar for 2018

Company Release no. 26/2017To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 29 December 2017 Veloxis Pharmaceuticals Announces Financial Calendar for 2018 Veloxis Pharmaceuticals A/S today announced ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks